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The necrosome is a protein complex required for signaling in
cells that results in necroptosis, which is also dependent on
tumor necrosis factor receptor (TNF-R) signaling. TNF pro-
motes necroptosis, and its expression is facilitated by mitogen-
activated protein (MAP) kinase–activated protein kinase 2
(MK2) but is inhibited by the RNA-binding protein tristetrapro-
lin (TTP, encoded by the Zfp36 gene). We have stimulated
murine macrophages from WT, MyD88/, Trif/, MyD88/
Trif/, MK2/, and Zfp36/ mice with graded doses of
lipopolysaccharide (LPS) and various inhibitors to evaluate the
role of various genes in Toll-like receptor 4 (TLR4)–induced
necroptosis. Necrosome signaling, cytokine production, and
cell death were evaluated by immunoblotting, ELISA, and cell
death assays, respectively. We observed that during TLR4 sig-
naling, necrosome activation is mediated through the adaptor
proteins MyD88 and TRIF, and this is inhibited by MK2. In the
absence of MK2-mediated necrosome activation, lipopolysac-
charide-induced TNF expression was drastically reduced, but
MK2-deficient cells became highly sensitive to necroptosis even
at low TNF levels. In contrast, during tonic TLR4 signaling,
WT cells did not undergo necroptosis, even when MK2 was dis-
abled. Of note, necroptosis occurred only in the absence of TTP
and was mediated by the expression of TNF and activation of
JUN N-terminal kinase (JNK). These results reveal that TTP
plays an important role in inhibiting TNF/JNK-induced necro-
some signaling and resultant cytotoxicity.
Toll-like receptor stimulation results in the activation of
NF-B, interferon regulatory factor, and MAPK2 pathways and
consequent expression of inflammatory cytokines and chemo-
kines (1, 2). The expression of cytokines such as TNF is mod-
ulated through posttranscriptional mechanisms. MAP kinase-
activated protein kinase 2 (MK2) and the RNA-binding protein
tristetraprolin (TTP) have opposite impact on TNF expres-
sion as Mk2/ cells express reduced levels of TNF in
response to TLR signaling (3), whereas TTP-deficient cells
express high levels of TNF that is associated with inflamma-
tion and autoimmunity (4, 5). The p38MAPK/MK2 pathway sta-
bilizes TNF mRNA and stimulates its translation in part by
inactivating (phosphorylating) TTP, which leads to an impair-
ment in the binding of TTP to the AU-rich elements of
TNF-mRNA (3, 6–10).
Engagement of the TNF-R has been reported to promote
NF-B signaling, and has been shown to be facilitated by the recep-
tor interacting protein kinase-1 (RipK1) (11). Cellular inhibitor of
apoptosis proteins (cIAPs) maintain RipK1 in this prosurvival
complex (12). Upon degradation of cIAPs through second mito-
chondrial inhibitor of apoptosis (SMAC), RipK1 undergoes ubiq-
uitin editing and participates in two cell death platforms: the
ripoptosome and the necrosome (13, 14). The ripoptosome com-
plex consists of RipK1, RipK3, FADD, and caspase-8, which
induces apoptotic cell death (15). When caspase-8 activity is inhib-
ited, it allows further interaction of the complex with RipK3 and
MLKL (called the necrosome complex), which results in phos-
phorylation and consequent trimerization of MLKL and cell death
by necroptosis (13, 16–21).
In addition to TNF-R engagement, TLR signaling in the absence
of caspase activity results in the assembly of an necroptosis (22–24)
The pathological role of necroptosis has been revealed in various
chronic diseases (25–33). Recently, it was reported that the treat-
ment of myeloid leukemic cells with SMAC mimetic failed to
induce TNF expression and ripoptosome induced cell death
unless MK2 was inhibited (34). Furthermore, MK2 was shown to
induce an inhibitory phosphorylation at Ser-321 on RipK1 in mye-
loid leukemic cells that restricted SMAC mimetic–induced cell
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death (34–37). However, this enhancement of cell death by the
inhibition of MK2 was not dependent on MLKL or RipK3 but
required the kinase function of RipK1 (34).
Here we evaluated the impact of MK2 and TTP in macro-
phages, and we demonstrate that TTP inhibits necrosome acti-
vation during tonic TLR signaling through the inhibition of
TNF and JNK expression/activation.
Results
MyD88 and TRIF signaling promote necroptosis of
macrophages
Necrosome signaling is induced in cells by engagement of
TLRs or cytokine receptors (TNF-R/IFNAR) signaling in the
absence of caspase-8 activity (17, 38). We stimulated macro-
phages with various concentrations of the TLR4 ligand LPS in
the presence of a high concentration of the pan-caspase inhib-
itor zVAD-fmk (50 M) to identify the relative concentration of
LPS required to induce cell death by necroptosis. To confirm
the mechanism of cell death as necroptosis, we treated cells
with necrostatin-1 (Nec-1) to inhibit the kinase region of RipK1
and consequent RipK1–RipK3 interaction. Our results indicate
that a minimal concentration of 200 pg/ml of LPS is required to
induce necroptosis of macrophages (Fig. 1A). Furthermore, at
10 ng/ml of LPS, 50% cell death of macrophages occurred by 6 h
post stimulation, whereas at 0.1 ng/ml LPS, 50% cell death
occurred at 24 h (Fig. 1B). Necroptosis was not induced when
Figure 1. TRIF and MyD88 synergize to induce necroptosis in macrophages during stimulation with high dose of LPS. A and B, bone marrow– derived
macrophages (BMMs) were treated with zVAD-fmk (50 M) and different concentrations of LPS, and cell viability was evaluated by MTT assay at 24 h (A) or at
various time intervals post stimulation (B). C–J, BMMs were generated from WT or various knockout mice indicated in the figure and treated with LPS (100
ng/ml) and zVAD-fmk (50 M). Cell viability was evaluated by MTT assay (24 h) (C and J), alamarBlue assay (24 h) (D), or at 18 h by Zombie Yellow assay (E). Cell
extracts were collected at various time intervals and the expression/activation of various proteins evaluated by Western blotting (F and G). Production of TNF
(ELISA) and IFN-I (bioassay) was measured in cell supernatants collected at 24 h (H). A graphic version of results is shown in panel I. Cells were also treated with
LPS and zVAD-fmk as mentioned above and p38MAPK inhibitor (LY2228820, 4 M) or MK2 inhibitor (PF3644022, 5 M) (J), and cell death was evaluated at 24 h
by MTT assay. Representative data of one experiment of three similar experiments are shown. Graphs show the percentage of viable cells  S.D. relative to
controls. Each experiment was repeated three times. *, p  0.05; **, p  0.01; ***, p  0.001; ****, p  0.0001.
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the concentration of LPS was reduced to 0.01 ng/ml. This sug-
gests that higher concentrations of LPS accelerate the timing of
necroptosis. We stimulated primary macrophages with high
(100 ng/ml) (Fig. 1, A, C–I) or low (1 ng/ml) (Fig. S1, A–F)
concentration of LPS, and/or zVAD-fmk (50 M) and measured
cell death at 24 h. Both at high and low concentration of LPS,
cell death depended on RipK3 and was rescued by the RipK3
inhibitor GSK872 (Fig. 1C and Fig. S1A). Whereas Ifnar1/
macrophages showed resistance against necroptosis at both
LPS concentrations (Fig. 1C and Fig. S1A), Tnfr2/ macro-
phages showed protection only in response to stimulation with
low concentration of LPS (Fig. S1A). Thus, higher concentra-
tion of LPS shifts the dependence of cell death less toward
TNFR2 and more toward IFN-R. There was no impact
of TNFR1 on necroptosis. Although we have previously
reported that TRIF-signaling promotes necroptosis of macro-
phages (38), our results indicate that resistance against necrop-
tosis induced by high or low concentration of LPS occurs only
when both MyD88 and TRIF-signaling pathways are disabled
(Fig. 1, D and E and Fig. S1B). Combined deficiency in MyD88
and Trif compromised necrosome signaling in macrophages as
revealed by lack of Ser-166 phosphorylation of RipK1 and unde-
tectable Ser-345 phosphorylation of MLKL (Fig. 1F). Further-
more, the total phosphorylation of RipK1 (upper band) was
undetectable in MyD88/Trif/ macrophages (Fig. 1F). We
further observed that the phosphorylation of RipK3 was
reduced in Trif/ but completely inhibited in MyD88/
Trif/ macrophages (Fig. 1G). This suggests that both TLR4
adaptor proteins synergize to induce necroptosis with TRIF
playing a more dominant role over MyD88. We observed that
MyD88 promoted the expression of TNF whereas TRIF
induced IFN-I. The expression of both cytokines was inhibited
only in macrophages with double deficiency of TRIF and
MyD88 (Fig. 1H and Fig. S1C).
Interestingly, the activation of p38MAPK was reduced in
MyD88/ and Trif/ macrophages but was undetectable in
MyD88/Trif/ macrophages (Fig. 1F). Thus, despite little
p38MAPK phosphorylation in MyD88/Trif/ macrophages,
there was poor necroptosis of macrophages. This result is sur-
prising because p38MAPK pathway has been recently shown to
induce an inhibitory phosphorylation of RipK1 and inhibit cell
death (35–37). Because we observed that the phosphorylation
of RipK1 (Ser-166)-dependent necroptosis was also inhibited in
MyD88/Trif/ macrophages, this result suggests that the
inhibition of the p38MAPK-induced inhibitory phosphorylation
of RipK1 does not necessarily drive the cells toward necroptosis
in the absence of TNF and IFN-I.
Because p38MAPK and the downstream kinase MK2 pro-
motes TNF expression by macrophages following LPS treat-
ment (3), we evaluated the impact of p38MAPK inhibitor
(LY2228820, 4 M) or MK2 inhibitor (PF3644022, 5 M) on
necroptosis induced by high (Fig. 1I) or low (Fig. S1D) concen-
trations of LPS. There was no appreciable increase in necrop-
tosis when the p38MAPK pathway was disabled. Similar results
were observed with Mk2/ macrophages (Fig. 1I and Fig. S1E).
Total phosphorylation of RipK1 (upper band) was inhibited in
Mk2/ cells and there was a slight increase in the Ser-345
phosphorylation of MLKL at earlier time period (Fig. S1F).
MK2 promotes TNF expression but impairs the sensitivity of
cells to necroptosis at lower levels of TNF
Whereas induction of necroptosis in macrophages requires
high concentrations of zVAD-fmk (25 M) (Fig. 2A), lower
concentrations are needed to inhibit caspase activity (39). We
therefore revised our experimental model and treated cells with
LPS (1 ng/ml) and a reduced concentration of zVAD-fmk (10
M) that does not induce significant necroptosis (Fig. 2A) to
determine whether the inhibition of p38MAPK induces their
sensitivity to cell death under these conditions. Our results
indicate that the inhibition of p38MAPK makes the cells signifi-
cantly susceptible to cell death (Fig. 2B), which correlates with
Ser-345 phosphorylation of MLKL (Fig. 2C). We observed that
the inhibition of p38MAPK accelerated the kinetics and magni-
tude of necroptosis (Fig. 2D) compared with the cells that did
not receive the p38MAPK inhibitor (Fig. 1B). Induction of cell
death by the inhibition of p38MAPK was still dependent on
RipK3, TNF (Fig. 2E), and MLKL (Fig. 2F) further confirming
the mechanism of cell death to be necroptosis. In the absence of
the p38MAPK inhibitor, there was no detectable cell death in
WT, RipK3/, or TNF/ macrophages upon treatment
with LPS (1 ng/ml) and low level of zVAD-fmk (10 M) (Fig.
S2A). Similar results were obtained with the MK2 inhibitor (Fig.
2G). To further confirm the role of MK2, we tested the cell
death of Mk2/ macrophages and observed that the defi-
ciency of MK2 promotes significantly increased cell death when
cells are treated with reduced zVAD-fmk concentration (Fig.
2H). Furthermore, Mk2/ macrophages displayed an absence
of overall RipK1 phosphorylation (upper band), and an increase
in the stimulatory phosphorylation of RipK1 (Ser-166) and that
was associated with phosphorylation of RipK3 and MLKL (Fig.
2I). We observed that when necroptosis was induced by treat-
ment of cells with LPS (1 ng/ml)  zVAD-fmk (10 M) 
p38MAPK inhibitor (4 M), cell death was mainly dependent on
TRIF at 6 h post stimulation of cells (Fig. S2B). However, at 24 h
post stimulation, complete rescue of cell death was observed
only when both MyD88 and TRIF were disabled (Fig. 2J and Fig.
S2C), suggesting that both adaptor proteins synergize to pro-
mote necroptosis under these conditions.
We observed that the expression of TNF was potently
reduced in Mk2/ cells in response to stimulation with LPS
(Fig. S2D) or LPSzVAD-fmk (Fig. 2K), although cell death
occurring in the absence of MK2 is TNF dependent (Fig. 2G).
To reconcile this paradox, we treated Tnfa/ macrophages
with LPS (1 ng/ml)zVAD-fmk (10 M) in the presence of
increasing concentrations of recombinant TNF. Our results
indicate that the inhibition of MK2 or p38MAPK makes macro-
phages highly sensitive (100-fold) to minimal concentrations
of TNF required to induce cell death (Fig. 2L and Fig. S2E).
These results suggest that the inhibition of p38MAPK/MK2 sig-
naling increases the sensitivity of macrophages to necroptosis
induced by very low levels of TNF.
p38MAPK restricts necroptosis induced by the inhibition of
caspase-8
We observed that when we use higher concentration (50
M) of the pan-caspase inhibitor zVAD-fmk, potent necrop-
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tosis is induced in macrophages, and addition of the
p38MAPK inhibitor has negligible impact (Fig. 1J). However,
when the concentration of zVAD-fmk is lowered to 10 M,
then necroptosis is induced only when the p38MAPK pathway
is inhibited (Fig. 2B). Thus, the use of higher zVAD-fmk
concentration masks the important role of p38MAPK in the
inhibition of necrosome signaling. Interestingly, treatment
of macrophages with LPS (1 ng/ml) and the specific
caspase-8 inhibitor (zIETD-fmk, 50 M) or another pan-
caspase inhibitor (Q-VD-OPh, 50 M) did not induce
necroptosis (Fig. 2M). These results suggest that zVAD-fmk
is uniquely able to induce necroptosis. Interestingly, we
observed that zIETD-fmk does induce necroptosis of macro-
phages only when p38MAPK is inhibited (Fig. 2, M and N). In
addition to zIETD-fmk, treatment of cells with Q-VD-OPh
resulted in cell death only upon co-treatment with LPS and
p38MAPK inhibitor (Fig. 2M). Because the zIETD-fmk
induced potent necrosome signaling in macrophages only
when p38MAPK/MK2 signaling was inhibited, this suggests
that zIETD-fmk was functional as a caspase-8 inhibitor. Fur-
thermore, treatment of macrophages with LPS zIETD-
fmkp38MAPK inhibitor resulted in the phosphorylation of
MLKL (Fig. 2O).
It has been suggested that zVAD-fmk treatment results in
necroptosis, because it blocks caspase-8 – cFLIPs heterodimer
better than the zIETD-fmk or Q-VD-OPh (40, 41). We there-
Figure 2. p38MAPKpathway inhibits necrosome signaling in macrophages only at reduced concentration of LPS. A, BMMs were treated with LPS (1
ng/ml) and different concentrations of zVAD-fmk. B–L, BMMs were generated from WT and various knockout mice indicated in the figure and treated with LPS
(1 ng/ml) (B, C, E–L) or various concentrations of LPS (D), and a reduced concentration (10 M) of zVAD-fmk. M–P, a different pan-caspase inhibitor (Q-VD-OPh,
50 M) (M) and two caspase-8 inhibitors (zIETD-fmk, 50 M) (M-O) and Emricasan (EMR, 10 M) (P) were used in some experiments. Cell death was evaluated at
24 h by MTT assay (A, B, E–H, L–N), CCK8 assay (D, P) or at 18 h by Zombie Yellow assay (J). Cell extracts were collected at various time intervals and the
expression/activation of various proteins evaluated by Western blotting (C, I, O). Expression of TNF was measured in the supernatants collected at various time
intervals after stimulation of WT or Mk2/ macrophages with LPS (1 ng/ml)  zVAD-fmk (10 M) (K). Tnf/ macrophages were stimulated with LPS (1
ng/ml)  zVAD-fmk (10 M) and different concentrations of recombinant TNF in the presence or absence of p38MAPK/MK2 inhibitors, and cell death was
evaluated by MTT assay at 24 h (L). Panel L shows asymmetric sigmoidal curve fit analysis of experimental data shown in Fig. S2E. Graphs show the percentage
of viable cells  S.D. relative to controls. Representative data of one experiment of three similar experiments are shown. Each experiment was repeated three
times. ***, p  0.001; ****, p  0.0001.
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fore used another specific caspase-8 inhibitor, Emricasan,
which has increased specificity toward caspase-8 and blocks
cFLIP-caspase-8 heterodimers similar to zVAD-fmk (42). The
treatment of cells with LPS (1 ng/ml)Emricasan (10 M)
resulted in cell death, which was enhanced by co-treatment
with p38MAPK inhibitor (Fig. 2P). Cell death was rescued by
GSK872, indicating the mechanism of cell death to be necrop-
tosis. Additional experiments indicated that when the concen-
tration of Emricasan was reduced to 1 M, cell death was unde-
tectable in macrophages unless p38MAPK pathway was
inhibited (Fig. S2F). It has been shown that the phosphorylation
of RipK1 by TAK1 governs the induction of apoptosis or
necroptosis (43). We observed that the inhibition of TAK1
results in enhanced cell death of macrophages, and that was
comparable to what was observed with the p38MAPK inhibitor
(Fig. S2G).
TTP inhibits necrosome activation during tonic TLR4 signaling
Because TTP (Zfp36) is a downstream target of MK2
(MAPKAP2), we evaluated the role of TTP in necroptosis of
macrophages. Our results indicate that when Zfp-36/
macrophages are stimulated with 1 ng/ml of LPS and 25 M
zVAD-fmk, they undergo significantly more necroptosis (Fig.
S3). We reasoned that this regulation of necroptosis by TTP
may become more apparent at even more reduced concentra-
tions of LPS. We observed that when cells were stimulated with
very low dose of LPS (0.01 ng/ml), WT macrophages failed to
undergo cell death, whereas Zfp36-deficient macrophages dis-
played a slight increase in cell death (Fig. 3, A–C). Interestingly,
the inhibition of p38MAPK in WT cells did not induce any
detectable cell death at low LPS concentration, whereas the
inhibition of p38MAPK induced significant cell death in
Zfp36/ macrophages (Fig. 3, D–G). This induction of cell
death in Zfp36/ macrophages was because of necroptosis
because the inhibition of RipK3 by GSK872 rescued cell death.
Interestingly, the potent activation of necrosome, as revealed by
Ser-345 phosphorylation of MLKL and Ser-166 phosphoryla-
tion of RipK1, was observed only when p38MAPK pathway was
inhibited in Zfp36/ cells (Fig. 3H).
Because RipK1 has been shown to have cell death–indepen-
dent role in promoting cytokine synthesis through ERK1/2 and
NF-B activation (44), and TTP has been reported to promote
degradation of various signaling proteins in the NF-B pathway
(45), we evaluated the activation of NF-B by Western blotting.
There was an increase in the activation of NF-B in Zfp36/
macrophages (Fig. 3I). Comparable to the results obtained with
the inhibitor of p38MAPK, the inhibition of MK2 also resulted in
cell death in Zfp36/ cells (Fig. 3J). The inhibition of p38MAPK
pathway also resulted in enhanced cell death in Zfp36/ cells
when cells were treated with low concentration of LPS and the
specific inhibitor of caspase-8 (Emricasan) (42) (Fig. 3K). We
observed that the inhibition of TAK1 or p38MAPK resulted in
comparable enhancement in the induction of necroptosis in
Zfp36/ macrophages (Fig. S4A). The inhibition of p38MAPK
resulted in enhanced RipK3 phosphorylation in Zfp36/
macrophages (Fig. S4B).
The inhibition of necrosome signaling by TTP occurs through
abrogation of both TNF expression and JNK activation
Because regulation of TNF mRNA stability is critically de-
pendent on TTP (3), we evaluated the impact of TTP and
p38MAPK pathway on TNF expression in response to tonic
LPS stimulation. At a highly reduced concentration of LPS (0.01
ng/ml) and zVAD-fmk (10 M), the TNF production was
undetectable in WT cells but was significantly induced in
Zfp36/ cells particularly after inactivation of the p38MAPK
pathway (Fig. 4, A and B). Necroptosis of Zfp36/ macro-
phages, following stimulation with low level of LPS (10 pg/ml),
was partially inhibited by blocking TNFR-I and completely res-
cued by blocking TNFR-II (Fig. 4, C–F). This suggests that TTP
blocks necrosome signaling through regulation of TNFR signal-
ing. Addition of exogenous TNF to cells instead of LPS
resulted in induction of necroptosis in both WT cells and
Zfp36/ macrophages to the same degree (Fig. 4G), which
correlated with the Ser-166 phosphorylation of RipK1 and Ser-
345 phosphorylation of MLKL (Fig. 4H). This is in contrast to
the situation with LPS treatment where cell death and necro-
some activation was only observed in Zfp36/ macrophages
(Fig. 3, D–H). These results suggest that the difference in cell
death observed in WT and Zfp36/ macrophages following
LPS treatment must be due selective induction/maintenance of
TNF expression in Zfp36/ macrophages.
We observed that there was an increase in the expression of
cIAP1/2, JNK1/2, and pERK1/2 in Zfp36/ cells (Fig. 5A).
Activation of JNK1/2 was also detected only in Zfp36/ cells
upon the inhibition of the p38MAPK pathway (Fig. 5A). Knowing
that JNK1/2 signaling has been shown to promote necroptosis
(46), we treated macrophages with JNK1/2 inhibitor (SP60012,
50 M) and observed a total abrogation of TNF expression
(Fig. 5B), and rescue of cell death in Zfp36/ macrophages
(Fig. 5C).
Thus, these results indicate that when necrosome activation
is induced by very high concentrations of both LPS and the
pan-caspase inhibitor zVAD-fmk, the impact of p38MAPK/MK2
signaling on necroptosis is barely appreciable. The inhibitory
effect of p38MAPK/MK2 on necrosome signaling becomes
apparent only when the concentrations of LPS and zVAD-fmk
are reduced to low levels. Because TTP degrades TNF tran-
scripts (3), we predict that this results in complete abrogation of
TNF when cells are stimulated with low doses of LPS, and
consequently, no necrosome signaling ensues. However, abro-
gation of TTP is not sufficient to switch the cells to necroptosis
because MK2 still promotes the inhibitory phosphorylation of
RipK1. Thus, disabling both the TTP and MK2 pathways is
required to promote the necrosome activation of macrophages
(Fig. 6).
Discussion
TLR signaling of myeloid cells is a key driver of inflammatory
response that facilitates the control of pathogens (1). Rupture of
cells as a result of inflammatory cell death pathways results in
the release of DAMPs and further amplification of the inflam-
matory response, which can lead to impairment in host survival
(28). The triad of RipK1, caspase-8, and RipK3 maintains home-
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ostasis, and an imbalance in the expression/function of any one
of these proteins leads to host fatality because of over-activa-
tion of the others (47–50). Thus, regulation of cell death path-
ways is critical for maintenance of homeostasis. Although
caspase-8 is considered a bona fide regulator of necrosome sig-
naling, additional regulatory mechanisms of necrosome signal-
ing have been recently revealed (24, 34–37). In this report we
show that TTP plays a key role in inhibiting necrosome signal-
ing of macrophages.
Our results indicate that during necrosome signaling of WT
macrophages, p38MAPK/MK2 signaling does not impact
necroptosis of cells unless the concentration of zVAD-fmk is
reduced or caspase-8 inhibitor is specifically used. Although
caspase-8 is a potent inhibitor of necrosome signaling in fibro-
blasts, specific inhibition of caspase-8 by zIETD-fmk does not
result in necroptosis of macrophages even at high concentra-
tions (24). Although it was considered that the concentration of
the caspase-8 inhibitor used (50 M) may not be sufficient to
inhibit caspase-8, it inhibited necrosome signaling when
p38MAPK/MK2 signaling was also inhibited, suggesting that the
caspase-8 inhibitor is functional at that concentration. It is cur-
rently not clear why necroptosis in macrophages can be
induced by the pan-caspase inhibitor zVAD-fmk but not by the
caspase-8 inhibitor zIETD-fmk (24) or the other pan-caspase
inhibitor, Q-VD-OPh. Because cFLIP is an endogenous inhibi-
tor of caspase-8 (40) which interacts with caspase-8 as a het-
Figure 3. TTP regulates necrosome activation in response to tonic TLR4 signaling. A–J, WT and TTP (Zfp-36)/ macrophages were stimulated with LPS
(0.01 ng/ml) and zVAD-fmk (10 M). D–J, in some experiments, cells were also co-treated with inhibitors against p38MAPK (LY2228820, 4 M) (D–I) or MK2
(PF3644022, 5 M) (J). Cell death was evaluated at 24 h by MTT assay (A, D, and J), by Zombie Yellow assay (B, C, E, and F), or by propidium iodide/Hoechst staining
(G). Western blot analysis was performed on cell extracts collected at various time intervals (H and I). WT and TTP (Zfp-36)/ macrophages were stimulated
with LPS (0.01 ng/ml) and Emricasan (EMR) (500 nM)  inhibitor against p38MAPK (LY2228820, 4 M), and cell death was evaluated 24 h later by CCK8 assay (K).
Representative data of one experiment of three similar experiments are shown. Graphs show the percentage of viable cells  S.D. relative to controls. Each
experiment was repeated three times. *, p  0.05; ***, p  0.001; ****, p  0.0001.
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erodimer (41), it is conceivable that zVAD-fmk uniquely inhib-
its the caspase-8 – cFLIPs heterodimer better than the zIETD or
Q-VD-fmk.
We have reported previously that during necrosome signal-
ing in macrophages, TLR4-engagement induces the phospho-
rylation of RipK1 at Thr-235 and Ser-313 (51). Recently, a new
inhibitory phosphorylation of RipK1 was reported at Ser-321 in
myeloid leukemia cells following treatment with SMAC mimet-
ics, and that was mediated by MK2 (34 –37). However, this
enhancement of leukemic cell death that was induced by the
inhibition of MK2 was not dependent on MLKL or RipK3 but
required the kinase function of RipK1 (34). The role of MK2 in
necroptosis was evaluated following treatment of MEFs with
TNFSMAC-mimeticzVAD-fmk, and this was reported to
be enhanced by the inhibition of MK2 (37). Although these
studies did not evaluate the impact of MK2 in TLR4-induced
necrosome signaling of macrophages, we did not observe any
significant impact of MK2 when cells were stimulated with tra-
ditional doses of LPS (1 or 100 ng/ml) and zVAD-fmk (50 M)
required to induce necroptosis of macrophages. Rather, we
observed that necroptosis was induced only when cells were
stimulated with very low doses of LPS (1 ng/ml) and zVAD-fmk
(10 M), and the p38MAPK pathway was inhibited. Furthermore,
our results also indicate that the inhibition of the p38MAPK
pathway enhances necroptosis induced by TNFzVAD-fmk;
however, this was not impacted by Zfp-36 (Fig. 4G). We have
revealed that the role of Zfp-36 is mainly related to expression
of TNF when TLR4 signaling is at tonic levels. Under these
conditions, the inhibition of p38MAPK pathway by itself fails to
induce necroptosis in WT cells (Fig. 3D). We believe that sig-
naling mechanisms that operate at very low levels of stimulants
are physiologically more relevant as they may exercise a greater
impact on homeostasis.
We have previously reported that the higher molecular
weight band of RipK1 is the phosphorylated version of this pro-
tein (38). Because this phosphorylation of RipK1 was inhibited
in MK2-deficient cells, it appears that the predominant phos-
phorylation of RipK1 in response to TLR signaling is inhibitory
Figure 4. The inhibition of necroptosis by Zfp-36 depends on TNFR signaling. A–H, WT and Zfp36/macrophages were stimulated with LPS (0.01 ng/ml)
and zVAD-fmk (10 M). Some cells were also co-treated with inhibitors against p38MAPK (LY2228820, 4 M) (A, C, and D–H), MK2 (PF3644022, 5 M) (B) or with
antibodies against TNFR1 (25 g/ml) (C and F) or TNFR2 (25 g/ml) (D and F). Expression of TNF was measured by ELISA in the supernatants collected at 6 h
(A and B). Cell death was evaluated at 24 h by alamarBlue assay (C, D, and G), at 18 h by Zombie Yellow assay (E and F). Western blotting was performed on cell
extracts collected at various time intervals (H). Representative data of one experiment of three similar experiments are shown. Graphs show the percentage of
viable cells  S.D. relative to controls. Each experiment was repeated three times. *, p  0.05; **, p  0.01; ***, p  0.001.
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in nature and is mediated by MK2. The knockdown of RipK1
has been shown to enhance necroptosis of human monocytic
THP1 cells (52), suggesting that RipK1 scaffold may function
more as an inhibitor rather than activator of necroptosis. Inter-
estingly, disabling p38MAPK/MK2 results in amplification of the
stimulatory RipK1 phosphorylation (Ser-166) while completely
obliterating the inhibitory phosphorylation, and this dichot-
omy becomes more pronounced when necrosome stimulation
is reduced, particularly when TTP is also disabled. It has been
shown that direct phosphorylation of RipK1 at Ser-321 by MK2
suppresses RipK1 Ser-166 autophosphorylation and inhibits its
ability to bind FADD/caspase-8 and induce RipK1-kinase– de-
pendent apoptosis and necroptosis (37).
We have reported that IFNAR1 signaling (53), and particu-
larly the downstream transcription factor complex ISGF3, is
required for necrosome activation in macrophages (38).
Recently, TNF-R2 signaling has been shown to be required for
necroptosis of macrophages that depends on IFNAR1 signaling
(54). This explains why necrosome signaling depends on
IFNAR1 and TNFR2 particularly when a relatively reduced
dose of LPS (1 ng/ml) is used. It is not clear why necroptosis
becomes less dependent on TNFR2 when the concentration of
LPS is increased further to 100 ng/ml. An interesting paradox
that we have revealed here is that during necrosome signaling
the levels of TNF are substantially reduced in MK2-deficient
macrophages, yet these cells become highly susceptible to
TNF-dependent necroptosis. We have shown that MK2 defi-
ciency results in increased sensitivity of macrophages to
necroptosis at highly reduced TNF concentrations.
Our results reveal that the p38MAPK and TTP pathways syn-
ergize to regulate necrosome signaling, and this synergistic reg-
ulation of necrosome signaling achieves a greater significance
when the concentrations of LPS and zVAD-fmk are reduced.
According to our model, TTP inhibits TNF expression when
the TLR4 signaling is very low, and TNF is required for necro-
some signaling. The inhibition of TTP does not enhance
necroptosis because MK2 is still able to induce an inhibitory
phosphorylation on RipK1 and hence inhibit necroptosis. Thus,
disabling both TTP and MK2 results in necroptosis.
It has been previously reported that transfection of the
human embryonic kidney cell line HEK293 with a TTP and
XIAP-expressing plasmid results in maintenance of RipK1
expression through degradation of XIAP and cIAP2 causing
increased cell death (55). Our Western blots did not reveal any
impact of TTP on the expression of RipK1 (Fig. 5, A and B),
although we did observe increased expression of cIAP1/2 and
XIAP in Zfp36-deficient macrophages. However, IAPs inhibit
ripoptosome-induced cell death (15, 39), without having any
Figure 5. The inhibition of necroptosis by Zfp-36 depends on JNK signal-
ing. A–C, WT and Zfp36/ macrophages were stimulated with LPS (0.01
ng/ml) and zVAD-fmk (10 M). Some cells were also co-treated with inhibitors
against p38MAPK (LY2228820, 4 M) (A–C), or MK2 (PF3644022, 5 M) (B and
C), or JNK1/2 (SP60012, 50 M) (B and C). Cell death was evaluated at 24 h by
alamarBlue assay (A, C) and the expression of TNF was measured in the
supernatants at 6 h post stimulation (B). Representative data of one experi-
ment of three similar experiments are shown. Graphs show the percentage of
viable cells  S.D. relative to controls. Each experiment was repeated three
times. ***, p  0.001.
Figure 6. Regulation of necrosome signaling by TTP. Tonic TLR4 engage-
ment in macrophages leads to expression of TNF through Myd88 signaling
(1). TNF mRNA is rapidly degraded by TTP through recognition of AU-rich
regions (2). As a consequence, less TNF is available for TNF-receptor signal-
ing and activation of JNK1/2 (3). Small levels of TNF bind to the TNF-receptor
(4) which is sufficient to induce phosphorylation of TAK1, P38, MK2, and Ser-
166 –RipK1 (5). MK2 induces an inhibitory Ser-321 phosphorylation of RipK1
(6). As a consequence, RipK3 fails to phosphorylate MLKL and mediate
necroptosis (7). TTP regulates the level of TNF which is the critical first step in
promoting the activation of RipK1.
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impact on necrosome signaling and necroptosis (56). It
remains to be seen whether the increased expression of XIAP
in Zfp36-deficient macrophages results in reduced ripopto-
some-induced cell death following treatment with a SMAC
mimetic. In contrast to the effect of RipK1 in ripoptosome
signaling, RipK1 has been shown to inhibit necrosome sig-
naling (52). Similar to necrosome signaling, TTP was
recently shown to inhibit the expression of NLRP3 inflam-
masome-mediated cell death (57). Thus, we believe that the
regulation of TNF expression by TTP and induction of the
inhibitory phosphorylation on RipK1 by MK2 result in syn-
ergistic inhibition of necrosome signaling in macrophages
(Fig. 6). Both, Zfp-36- and MK2-deficient mice have major
phenotypic impact in vivo (3, 4). We expect that necrosome
signaling is dysregulated and facilitates the effects observed
in the inflammatory response in these mice.
Experimental procedures
Mice
C57BL/6J (stock no. 0664), TNF-R1/ (stock no. 03242),
TNF-R2/ (stock no. 02620), TNF/ (stock no. 05540),
Trif-mutant (stock no. 05037), and MyD88/ (stock no.
09088) were obtained from The Jackson Laboratory (Bar Har-
bor, ME). RipK3/ were obtained from Dr. Vishva Dixit
(Genentech, South San Francisco, California). Homozygous
mating strategy was used to breed the mice mentioned above.
Heterozygous breeding strategy was used to maintain Zfp-
36/ and MK2/ mice because of poor breeding associated
with homozygous breeding. When using macrophages from
Zfp-36/ and MK2/ mice, macrophages from littermate
/ mice were used as WT controls. Mice were maintained at
the animal facility of the University of Ottawa, Faculty of Med-
icine. All procedures were approved by University of Ottawa
Animal Care Committee.
Macrophages and cell cultures
Macrophages (BMM) were generated from the bone marrow
of the appropriate mouse strain after differentiating bone mar-
row cells with M-CSF (5 ng/ml) for 7–12 days. Cells were cul-
tured in RPMI  8% FBS. Cells were plated in 96- or 24-well
plates in RPMI8%FBS and various reagents added after over-
night incubation. At various time intervals, cell death and acti-
vation of various proteins were evaluated.
Cell death assays
Cell viability was measured by various approaches. For col-
orimetric assay of cell death measurement, MTT was added to
cells at a final concentration of 0.5 mg/ml and incubated at
37 °C for 2 h. Cells were lysed by adding 5 mM HCl in isopropyl
alcohol and vigorously pipette up and down to solubilize the
MTT crystals. Using Emax plate reader, optical density values
were obtained by measuring absorption at 570 nm with a refer-
ence wavelength of 650 nm. The data were normalized to
the corresponding stimulated control (i.e. LPSzVAD-fmk
treated cells were normalized to LPS treated cells whereas
TNFzVAD-fmk treated cells were normalized to TNF). In
some experiments cell viability was measured by CCK8 assay
(Enzo Life Sciences, Cat#ALX-850 – 039-K101). Optical den-
sity was measured at 450 nm and normalized to the corre-
sponding stimulation control.
As an alternative colorimetric assay, alamarBlue® (cat. no.
R7017, Sigma) was used at a final concentration of 0.04% dye
(Resazurin) and fluorescence was measured (excitation 530 nm,
emission 590 nm).
Cell death was also evaluated by immunofluorescence fol-
lowing staining with Hoëchst 33342 (2.5 g/ml; Invitrogen) and
propidium iodide (1:10 dilution; BD Pharmingen, 550825).
Cells were stained in RPMI lacking phenol for 25–30 min. to
distinguish live and dead cells. A Zeiss AxioObserver D1 micro-
scope and the AxioVision Rel. 4.8 program were utilized to
capture and analyze images. Cell death was also evaluated by
flow cytometry following staining of cells with Zombie Yel-
lowTM (BioLegend, San Diego, CA). Zombie YellowTM solution
(1:100 in PBS) was added into each well and the plate was incu-
bated at room temperature, in the dark, for 15–30 min before
washing with 100 l FACS buffer (PBS, 1% BSA, 1 mM EDTA)
once. Samples were fixed in 1% paraformaldehyde and acquired
on LSR Fortessa Flow cytometer.
Western blotting
Cells were washed with cold PBS and were directly lysed in
1% SDS lysis buffer with 1% -mercaptoethanol and transferred
to 1.5 ml Eppendorf tubes. Samples were boiled instantly at
96 °C and frozen at 20 °C for future use. Lysates were run on
polyacrylamide gel, based on the size of the proteins of interest.
Gels were typically loaded with 25 l of lysate and run at 135 V
for 75 min. The transfer was run at 100 V for an hour. Once
transferred, 5% skim milk or 5% BSA was used for 1 h to block
the membrane. Primary antibodies diluted in appropriate
blocking buffer (5% milk or BSA), were added to the membrane
and incubated overnight on a shaker at 4 °C. The following anti-
bodies were used: Mouse anti-Ripk1 (BD Biosciences, 610459),
rabbit anti–phospho-RipK1 Ser-166 (Cell Signaling Technol-
ogy, 31122), rabbit anti-RipK3 (ProSci Inc., 2283), rat anti-
MLKL monoclonal (MABC604, EMD Millipore, Billerica, MA),
rabbit anti-phospho MLKL(S345) monoclonal (D6E3G, Cell
signaling, CA), mouse anti--actin (sc-81178, Santa Cruz,
TX), rabbit anti p38MAPK (Cell Signaling Technology,
8690), rabbit anti-p-p38 (Cell Signaling Technology, 4511),
anti-mouse MK2 (Cell Signaling Technology, 3042), anti-
mouse p-MK2 (Cell Signaling Technology, 3007), rabbit
anti-mouse FLIP (Abcam, 8421), mouse anti-mouse FADD
(Enzo, ADI-AMM-212-E), rabbit anti-mouse P65 (Cell Sig-
naling Technology, 8242), rabbit anti-mouse phospho (Ser-
536) P65 (Cell Signaling Technology, 3033), rabbit anti-
mouse XIAP (Cell Signaling Technology, 14334), Rabbit
anti-mouse ERK (Cell Signaling Technology, 4695), rabbit
anti-mouse phospho (T202/Y204) ERK (Cell Signaling Tech-
nology, 4370), rabbit anti JNK (Cell Signaling Technology,
9252), rabbit anti-mouse phospho (Thr-183/Tyr-185) JNK
(Cell Signaling Technology, 9251), and rabbit anti-mouse
cIAP1/2 (Cyclex, CY-P1041). Results were quantified using
ImageJ software to perform the densitometric analysis.
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p38MAPK inhibitor (LY2228820, S4279) and MK2 inhibitor
(PF3644022, S1494) were obtained from Selleck Chemicals
(Houston, TX). GSK872 (GLXC-03990) was obtained from
Glixx (Southborough, MA). Necrostatin-1 (Nec-1 9037), ultra-
pure LPS (Escherichia coli 0111:B4, (L4524) and MTT (M5655)
were obtained from Sigma-Aldrich). zVAD-FMK (A1902) was
obtained from ApexBio (Houston, TX). Caspase 8 inhibitor
(C8I) (zIETD-fmk, 1064 –20C) was obtained from BioVision
(Milpitas, CA). JNK inhibitor (SP60012) was obtained from Sig-
ma-Aldrich (S5567). TAK1 inhibitor ((5Z)-7-oxozeaenol) was
obtained from Tocris (3604). Emricasan was obtained from
Selleck Chemicals (S7775). Recombinant mouse TNF (410-
MT) was obtained from R&D Systems (Minneapolis, MN).
Cytokine analysis
Production of TNF was measured in supernatants collected
at 6 h by BD Biosciences optEIA ELISA kit (eBioscience). The
expression of IFN-I was measured using a reporter cell line.
ISRE-L929 cells were seeded at 5  104 cells per well in a 96-well
tissue culture plate and incubated at 37 °C with 40 l of culture
supernatants for 4 h. Using the luciferase assay system kit (Pro-
mega, E1500), the luminescence was measured by a Molecular
Devices Emax plate reader and data were analyzed by SoftMax
Pro and Graphpad Prism 6.
Statistical analyses
Statistical analysis was determined by Student’s t test using
GraphPad Prism 8 software (La Jolla, California).
Author contributions—A. A. data curation; A. A., N. A. A., and S. H.
investigation; A. A. and N. A. A. methodology; N. A. A. validation;
N. A. A., S. H., M. G., P. J. B., and S. S. writing-review and editing;
D. J. S., C. T., E. S. A., M. G., P. J. B., and S. S. resources; D. J. S., C. T.,
and S. S. writing-original draft; S. S. conceptualization; S. S. software;
S. S. supervision; S. S. project administration.
References
1. Brodsky, I. E., and Medzhitov, R. (2009) Targeting of immune signalling
networks by bacterial pathogens. Nat. Cell Biol. 11, 521–526 CrossRef
Medline
2. Eckmann, L., and Kagnoff, M. F. (2001) Cytokines in host defense against
Salmonella. Microbes. Infect. 3, 1191–1200 CrossRef Medline
3. Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk,
H. D., and Gaestel, M. (1999) MAPKAP kinase 2 is essential for LPS-
induced TNF- biosynthesis. Nat. Cell Biol. 1, 94 –97 CrossRef Medline
4. Taylor, G. A., Carballo, E., Lee, D. M., Lai, W. S., Thompson, M. J., Patel,
D. D., Schenkman, D. I., Gilkeson, G. S., Broxmeyer, H. E., Haynes, B. F.,
and Blackshear, P. J. (1996) A pathogenetic role for TNF in the syndrome
of cachexia, arthritis, and autoimmunity resulting from tristetraprolin
(TTP) deficiency. Immunity 4, 445– 454 CrossRef Medline
5. Carballo, E., Lai, W. S., and Blackshear, P. J. (1998) Feedback inhibition of
macrophage tumor necrosis factor- production by tristetraprolin. Sci-
ence 281, 1001–1005 CrossRef Medline
6. Hitti, E., Iakovleva, T., Brook, M., Deppenmeier, S., Gruber, A. D., Radzi-
och, D., Clark, A. R., Blackshear, P. J., Kotlyarov, A., and Gaestel, M. (2006)
Mitogen-activated protein kinase-activated protein kinase 2 regulates tu-
mor necrosis factor mRNA stability and translation mainly by altering
tristetraprolin expression, stability, and binding to adenine/uridine-rich
element. Mol. Cell Biol. 26, 2399 –2407 CrossRef Medline
7. Neininger, A., Kontoyiannis, D., Kotlyarov, A., Winzen, R., Eckert, R.,
Volk, H. D., Holtmann, H., Kollias, G., and Gaestel, M. (2002) MK2 targets
AU-rich elements and regulates biosynthesis of tumor necrosis factor and
interleukin-6 independently at different post-transcriptional levels. J. Biol.
Chem. 277, 3065–3068 CrossRef Medline
8. Sabio, G., and Davis, R. J. (2014) TNF and MAP kinase signalling pathways.
Semin. Immunol. 26, 237–245 CrossRef Medline
9. Arthur, J. S., and Ley, S. C. (2013) Mitogen-activated protein kinases in
innate immunity. Nat. Rev. Immunol. 13, 679 – 692 CrossRef Medline
10. Carballo, E., Cao, H., Lai, W. S., Kennington, E. A., Campbell, D., and
Blackshear, P. J. (2001) Decreased sensitivity of tristetraprolin-deficient
cells to p38 inhibitors suggests the involvement of tristetraprolin in the
p38 signaling pathway. J. Biol. Chem. 276, 42580 – 42587 CrossRef
Medline
11. Meylan, E., Burns, K., Hofmann, K., Blancheteau, V., Martinon, F., Kelli-
her, M., and Tschopp, J. (2004) RIP1 is an essential mediator of Toll-like
receptor 3-induced NF-B activation. Nat. Immunol. 5, 503–507
CrossRef Medline
12. Conte, D., Holcik, M., Lefebvre, C. A., LaCasse, E., Picketts, D. J., Wright,
K. E., and Korneluk, R. G. (2006) Inhibitor of apoptosis protein cIAP2 is
essential for lipopolysaccharide-induced macrophage survival. Mol. Cell
Biol. 26, 699 –708 CrossRef Medline
13. Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny,
G. D., Mitchison, T. J., Moskowitz, M. A., and Yuan, J. (2005) Chemical
inhibitor of nonapoptotic cell death with therapeutic potential for ische-
mic brain injury. Nat. Chem. Biol. 1, 112–119 CrossRef Medline
14. Pasparakis, M., and Vandenabeele, P. (2015) Necroptosis and its role in
inflammation. Nature 517, 311–320 CrossRef Medline
15. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg,
F., Zachariou, A., Lopez, J., MacFarlane, M., Cain, K., and Meier, P. (2011)
The ripoptosome, a signaling platform that assembles in response to geno-
toxic stress and loss of IAPs. Mol. Cell 43, 432– 448 CrossRef Medline
16. Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., and
Chan, F. K. (2009) Phosphorylation-driven assembly of the RIP1-RIP3
complex regulates programmed necrosis and virus-induced inflamma-
tion. Cell 137, 1112–1123 CrossRef Medline
17. Christofferson, D. E., and Yuan, J. (2010) Necroptosis as an alternative
form of programmed cell death. Curr. Opin. Cell Biol. 22, 263–268
CrossRef Medline
18. Galluzzi, L., and Kroemer, G. (2008) Necroptosis: A specialized pathway of
programmed necrosis. Cell 135, 1161–1163 CrossRef Medline
19. Festjens, N., Vanden Berghe, T., and Vandenabeele, P. (2006) Necrosis, a
well-orchestrated form of cell demise: Signalling cascades, important me-
diators and concomitant immune response. Biochim. Biophys. Acta 1757,
1371–1387 CrossRef Medline
20. Hitomi, J., Christofferson, D. E., Ng, A., Yao, J., Degterev, A., Xavier, R. J.,
and Yuan, J. (2008) Identification of a molecular signaling network that
regulates a cellular necrotic cell death pathway. Cell 135, 1311–1323
CrossRef Medline
21. Declercq, W., Vanden Berghe, T., and Vandenabeele, P. (2009) RIP kinases
at the crossroads of cell death and survival. Cell 138, 229 –232 CrossRef
Medline
22. He, S., Liang, Y., Shao, F., and Wang, X. (2011) Toll-like receptors activate
programmed necrosis in macrophages through a receptor-interacting ki-
nase-3-mediated pathway. Proc. Natl. Acad. Sci. U.S.A. 108, 20054 –20059
CrossRef Medline
23. McComb, S., Cheung, H. H., Korneluk, R. G., Wang, S., Krishnan, L., and
Sad, S. (2012) cIAP1 and cIAP2 limit macrophage necroptosis by inhibit-
ing Rip1 and Rip3 activation. Cell Death Differ. 19, 1791–1801 CrossRef
Medline
24. McComb, S., Shutinoski, B., Thurston, S., Cessford, E., Kumar, K., and Sad,
S. (2014) Cathepsins limit macrophage necroptosis through cleavage of
Rip1 kinase. J. Immunol. 192, 5671–5678 CrossRef Medline
25. Kaczmarek, A., Vandenabeele, P., and Krysko, D. V. (2013) Necroptosis:
The release of damage-associated molecular patterns and its physiological
relevance. Immunity 38, 209 –223 CrossRef Medline
TTP regulates necrosome signaling













26. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010)
Molecular mechanisms of necroptosis: An ordered cellular explosion.
Nat. Rev. Mol. Cell Biol. 11, 700 –714 CrossRef Medline
27. Günther, C., Martini, E., Wittkopf, N., Amann, K., Weigmann, B., Neu-
mann, H., Waldner, M. J., Hedrick, S. M., Tenzer, S., Neurath, M. F., and
Becker, C. (2011) Caspase-8 regulates TNF--induced epithelial necrop-
tosis and terminal ileitis. Nature 477, 335–339 CrossRef Medline
28. Duprez, L., Takahashi, N., Van Hauwermeiren, F., Vandendriessche, B.,
Goossens, V., Vanden Berghe, T., Declercq, W., Libert, C., Cauwels, A.,
and Vandenabeele, P. (2011) RIP kinase-dependent necrosis drives lethal
systemic inflammatory response syndrome. Immunity 35, 908 –918
CrossRef Medline
29. Ito, Y., Ofengeim, D., Najafov, A., Das, S., Saberi, S., Li, Y., Hitomi, J., Zhu,
H., Chen, H., Mayo, L., Geng, J., Amin, P., DeWitt, J. P., Mookhtiar, A. K.,
Florez, M., et al. (2016) RIPK1 mediates axonal degeneration by promot-
ing inflammation and necroptosis in ALS. Science 353, 603– 608 CrossRef
Medline
30. Karunakaran, D., Geoffrion, M., Wei, L., Gan, W., Richards, L., Shangari,
P., DeKemp, E. M., Beanlands, R. A., Perisic, L., Maegdefessel, L., Hedin,
U., Sad, S., Guo, L., Kolodgie, F. D., Virmani, R., Ruddy, T., and Rayner, K. J.
(2016) Targeting macrophage necroptosis for therapeutic and diagnostic
interventions in atherosclerosis. Sci. Adv. 2, e1600224 CrossRef Medline
31. Ofengeim, D., Ito, Y., Najafov, A., Zhang, Y., Shan, B., DeWitt, J. P., Ye, J.,
Zhang, X., Chang, A., Vakifahmetoglu-Norberg, H., Geng, J., Py, B., Zhou,
W., Amin, P., Berlink Lima, J., Qi, C., Yu, Q., Trapp, B., and Yuan, J. (2015)
Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836 –1849
CrossRef Medline
32. Berger, S. B., Kasparcova, V., Hoffman, S., Swift, B., Dare, L., Schaeffer, M.,
Capriotti, C., Cook, M., Finger, J., Hughes-Earle, A., Harris, P. A., Kaiser,
W. J., Mocarski, E. S., Bertin, J., and Gough, P. J. (2014) Cutting edge: RIP1
kinase activity is dispensable for normal development but is a key regula-
tor of inflammation in SHARPIN-deficient mice. J. Immunol. 192,
5476 –5480 CrossRef Medline
33. Wang, W., Marinis, J. M., Beal, A. M., Savadkar, S., Wu, Y., Khan, M.,
Taunk, P. S., Wu, N., Su, W., Wu, J., Ahsan, A., Kurz, E., Chen, T., Yaboh,
I., Li, F., et al. (2018) RIP1 kinase drives macrophage-mediated adaptive
immune tolerance in pancreatic cancer. Cancer Cell 34, 757–774.e7
CrossRef Medline
34. Lalaoui, N., Hänggi, K., Brumatti, G., Chau, D., Nguyen, N. Y., Vasilikos, L.,
Spilgies, L. M., Heckmann, D. A., Ma, C., Ghisi, M., Salmon, J. M., Mat-
thews, G. M., de Valle, E., Moujalled, D. M., Menon, M. B., et al. (2016)
Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mi-
metics. Cancer Cell 29, 145–158 CrossRef Medline
35. Menon, M. B., Gropengießer, J., Fischer, J., Novikova, L., Deuretzbacher,
A., Lafera, J., Schimmeck, H., Czymmeck, N., Ronkina, N., Kotlyarov, A.,
Aepfelbacher, M., Gaestel, M., and Ruckdeschel, K. (2017) p38MAPK/
MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in
inflammation and infection. Nat. Cell Biol. 19, 1248 –1259 CrossRef
Medline
36. Dondelinger, Y., Delanghe, T., Rojas-Rivera, D., Priem, D., Delvaeye, T.,
Bruggeman, I., Van Herreweghe, F., Vandenabeele, P., and Bertrand,
M. J. M. (2017) MK2 phosphorylation of RIPK1 regulates TNF-mediated
cell death. Nat. Cell Biol. 19, 1237–1247 CrossRef Medline
37. Jaco, I., Annibaldi, A., Lalaoui, N., Wilson, R., Tenev, T., Laurien, L., Kim,
C., Jamal, K., Wicky John, S., Liccardi, G., Chau, D., Murphy, J. M., Bru-
matti, G., Feltham, R., Pasparakis, M., Silke, J., and Meier, P. (2017) MK2
phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66,
698 –710.e5 CrossRef Medline
38. McComb, S., Cessford, E., Alturki, N. A., Joseph, J., Shutinoski, B., Startek,
J. B., Gamero, A. M., Mossman, K. L., and Sad, S. (2014) Type-I interferon
signaling through ISGF3 complex is required for sustained Rip3 activation
and necroptosis in macrophages. Proc. Natl. Acad. Sci. U.S.A. 111,
E3206 –E3213 CrossRef Medline
39. Rijal, D., Ariana, A., Wight, A., Kim, K., Alturki, N. A., Aamir, Z., Ametepe,
E. S., Korneluk, R. G., Tiedje, C., Menon, M. B., Gaestel, M., McComb, S.,
and Sad, S. (2018) Differentiated macrophages acquire a pro-inflamma-
tory and cell death-resistant phenotype due to increasing XIAP and p38-
mediated inhibition of RipK1. J. Biol. Chem. 293, 11913–11927 CrossRef
Medline
40. Hughes, M. A., Powley, I. R., Jukes-Jones, R., Horn, S., Feoktistova, M.,
Fairall, L., Schwabe, J. W., Leverkus, M., Cain, K., and MacFarlane, M.
(2016) Co-operative and hierarchical binding of c-FLIP and caspase-8: A
unified model defines how c-FLIP isoforms differentially control cell fate.
Mol. Cell 61, 834 – 849 CrossRef Medline
41. Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P.,
Pop, C., Hakem, R., Salvesen, G. S., and Green, D. R. (2011) Catalytic
activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necro-
sis. Nature 471, 363–367 CrossRef Medline
42. Brumatti, G., Ma, C., Lalaoui, N., Nguyen, N. Y., Navarro, M., Tanzer,
M. C., Richmond, J., Ghisi, M., Salmon, J. M., Silke, N., Pomilio, G., Glaser,
S. P., de Valle, E., Gugasyan, R., Gurthridge, M. A., et al. (2016) The
caspase-8 inhibitor Emricasan combines with the SMAC mimetic birina-
pant to induce necroptosis and treat acute myeloid leukemia. Sci. Transl.
Med. 8, 339ra69 CrossRef Medline
43. Geng, J., Ito, Y., Shi, L., Amin, P., Chu, J., Ouchida, A. T., Mookhtiar, A. K.,
Zhao, H., Xu, D., Shan, B., Najafov, A., Gao, G., Akira, S., and Yuan, J.
(2017) Regulation of RIPK1 activation by TAK1-mediated phosphoryla-
tion dictates apoptosis and necroptosis. Nat. Commun. 8, 359 CrossRef
Medline
44. Najjar, M., Saleh, D., Zelic, M., Nogusa, S., Shah, S., Tai, A., Finger, J. N.,
Polykratis, A., Gough, P. J., Bertin, J., Whalen, M., Pasparakis, M.,
Balachandran, S., Kelliher, M., Poltorak, A., and Degterev, A. (2016) RIPK1
and RIPK3 kinases promote cell-death-independent inflammation by
Toll-like receptor 4. Immunity 45, 46 –59 CrossRef Medline
45. Tiedje, C., Diaz-Muñoz, M. D., Trulley, P., Ahlfors, H., Laaß, K., Blacks-
hear, P. J., Turner, M., and Gaestel, M. (2016) The RNA-binding protein
TTP is a global post-transcriptional regulator of feedback control in in-
flammation. Nucleic Acids Res. 44, 7418 –7440 CrossRef Medline
46. Cao, M., Chen, F., Xie, N., Cao, M. Y., Chen, P., Lou, Q., Zhao, Y., He, C.,
Zhang, S., Song, X., Sun, Y., Zhu, W., Mou, L., Luan, S., and Gao, H. (2018)
c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated
necroptosis through their kinase-dependent and -independent activities.
Cell Death Dis. 9, 1140 CrossRef Medline
47. Kaiser, W. J., Upton, J. W., Long, A. B., Livingston-Rosanoff, D., Daley-
Bauer, L. P., Hakem, R., Caspary, T., and Mocarski, E. S. (2011) RIP3
mediates the embryonic lethality of caspase-8-deficient mice. Nature 471,
368 –372 CrossRef Medline
48. Dillon, C. P., Weinlich, R., Rodriguez, D. A., Cripps, J. G., Quarato, G.,
Gurung, P., Verbist, K. C., Brewer, T. L., Llambi, F., Gong, Y. N., Janke, L. J.,
Kelliher, M. A., Kanneganti, T. D., and Green, D. R. (2014) RIPK1 blocks
early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157,
1189 –1202 CrossRef Medline
49. Dillon, C. P., Oberst, A., Weinlich, R., Janke, L. J., Kang, T. B., Ben-Moshe,
T., Mak, T. W., Wallach, D., and Green, D. R. (2012) Survival function of
the FADD-CASPASE-8-cFLIPL complex. Cell Rep. 1, 401– 407 CrossRef
Medline
50. Newton, K., Dugger, D. L., Wickliffe, K. E., Kapoor, N., de Almagro, M. C.,
Vucic, D., Komuves, L., Ferrando, R. E., French, D. M., Webster, J., Roose-
Girma, M., Warming, S., and Dixit, V. M. (2014) Activity of protein kinase
RIPK3 determines whether cells die by necroptosis or apoptosis. Science
343, 1357–1360 CrossRef Medline
51. Shutinoski, B., Alturki, N. A., Rijal, D., Bertin, J., Gough, P. J., Schlossm-
acher, M. G., and Sad, S. (2016) K45A mutation of RIPK1 results in poor
necroptosis and cytokine signaling in macrophages, which impacts in-
flammatory responses in vivo. Cell Death Differ. 23, 1628 –1637 CrossRef
Medline
52. Kearney, C. J., Cullen, S. P., Clancy, D., and Martin, S. J. (2014) RIPK1 can
function as an inhibitor rather than an initiator of RIPK3-dependent
necroptosis. FEBS J. 281, 4921– 4934 CrossRef Medline
53. Robinson, N., McComb, S., Mulligan, R., Dudani, R., Krishnan, L., and Sad,
S. (2012) Type I interferon induces necroptosis in macrophages during
infection with Salmonella enterica serovar Typhimurium. Nat. Immunol.
13, 954 –962 CrossRef Medline
54. Legarda, D., Justus, S. J., Ang, R. L., Rikhi, N., Li, W., Moran, T. M., Zhang,
J., Mizoguchi, E., Zelic, M., Kelliher, M. A., Blander, J. M., and Ting, A. T.
TTP regulates necrosome signaling













(2016) CYLD proteolysis protects macrophages from TNF-mediated au-
to-necroptosis induced by LPS and licensed by type I IFN. Cell Rep. 15,
2449 –2461 CrossRef Medline
55. Selmi, T., Alecci, C., dell’Aquila, M., Montorsi, L., Martello, A., Guizzetti,
F., Volpi, N., Parenti, S., Ferrari, S., Salomoni, P., Grande, A., and Zanocco-
Marani, T. (2015) ZFP36 stabilizes RIP1 via degradation of XIAP and
cIAP2 thereby promoting ripoptosome assembly. BMC Cancer 15, 357
CrossRef Medline
56. Alturki, N. A., McComb, S., Ariana, A., Rijal, D., Korneluk, R. G., Sun,
S.-C., Alnemri, E., and Sad, S. (2018) Triad3a induces the degradation of
early necrosome to limit RipK1-dependent cytokine production and
necroptosis. Cell Death Dis. 9, 592 CrossRef Medline
57. Haneklaus, M., O’Neil, J. D., Clark, A. R., Masters, S. L., and O’Neill, L. A. J.
(2017) The RNA-binding protein tristetraprolin (TTP) is a critical nega-
tive regulator of the NLRP3 inflammasome. J. Biol. Chem. 292,
6869 – 6881 CrossRef Medline
TTP regulates necrosome signaling













Tiedje, Emad S. Alnemri, Matthias Gaestel, Perry J. Blackshear and Subash Sad
Ardeshir Ariana, Norah A. Alturki, Stephanie Hajjar, Deborah J. Stumpo, Christopher
signaling in murine macrophages
Tristetraprolin regulates necroptosis during tonic Toll-like receptor 4 (TLR4)
doi: 10.1074/jbc.RA119.011633 originally published online February 24, 2020
2020, 295:4661-4672.J. Biol. Chem. 
  
 10.1074/jbc.RA119.011633Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/295/14/4661.full.html#ref-list-1




niversity on June 2, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
